Targeted Therapy In Cancer Management
.
Questions and Answers
- 1.
What targeted therapy in cancer management is ?
- 2.
State 3 differences between targeted therapy and chemotherapy
- 3.
Mention the targeted therapies of Beacon with the brand names & strengths for breast cancer
- 4.
Cetuximab and Regorafenib are both indicated in colorectal cancer. Can make some differences between these two drugs ?
- 5.
What is the basic difference between checkpoint inhibitors and other monoclonal antibodies ?
- 6.
Give 2 examples of PD-1 inhibitor with the name Beacon brand & strengths
- 7.
What is angiogenesis ? write an example of monoclonal antibody that block angiogenesis.
- 8.
Write the Beacon brand names with strengths of the targeted therapies for Philadelphia +ve CML
- 9.
Targeted anticancer drug targets:
- A.
A gene
- B.
An enzyme
- C.
A receptor
- D.
All of them
Correct Answer
D. All of themExplanation
The correct answer is "All of them" because targeted anticancer drugs can be designed to target specific genes, enzymes, or receptors that are involved in the growth and spread of cancer cells. By targeting these specific molecular targets, the drugs can inhibit their activity and prevent the progression of cancer. This approach allows for more precise and effective treatment options, as it focuses on the specific molecular abnormalities that are driving the cancer cells' growth and survival.Rate this question:
-
- 10.
Which of the following targeted therapy brands is indicated for T790M NSCLC?
- A.
Tagrix
- B.
Erlonix
- C.
Apalunix
- D.
Lapanix
Correct Answer
A. TagrixExplanation
Tagrix is the correct answer because it is a targeted therapy brand specifically indicated for T790M NSCLC (non-small cell lung cancer). This means that Tagrix is designed to target and treat this specific type of lung cancer, making it the appropriate choice for patients with T790M NSCLC.Rate this question:
-
- 11.
What is the preferred choice for NSCLC with EGFR mutation ?
- A.
Afatinib
- B.
Gefitinib
- C.
Erlotinib
- D.
Osimertinib
Correct Answer
D. OsimertinibExplanation
Osimertinib is the preferred choice for NSCLC with EGFR mutation because it is a third-generation EGFR tyrosine kinase inhibitor (TKI) that has shown superior efficacy and improved progression-free survival compared to other EGFR TKIs such as gefitinib, erlotinib, and afatinib. Osimertinib specifically targets the T790M mutation, which is the most common resistance mutation in EGFR-mutated NSCLC. Additionally, osimertinib has demonstrated better central nervous system penetration and a favorable safety profile. Therefore, it is considered the standard of care for NSCLC patients with EGFR mutation.Rate this question:
-
- 12.
Which of followings are the first line targeted therapies for hepatocellular cancer ?
- A.
Lenvatinib
- B.
Regorafenib
- C.
Cabozantinib
- D.
Sorafenib
Correct Answer(s)
A. Lenvatinib
D. SorafenibExplanation
Lenvatinib and Sorafenib are the first-line targeted therapies for hepatocellular cancer. These drugs have been approved by the FDA for the treatment of this specific type of cancer. They work by targeting specific molecules or pathways involved in the growth and spread of cancer cells. By inhibiting these targets, Lenvatinib and Sorafenib can help slow down the progression of hepatocellular cancer and improve patient outcomes. Regorafenib and Cabozantinib are also targeted therapies used in the treatment of hepatocellular cancer, but they are typically reserved for patients who have already received prior treatment with Sorafenib.Rate this question:
-
- 13.
Targeted therapies for prostate cancer?
- A.
Docetaxel
- B.
Ibrutinib
- C.
Apalutamide
- D.
Bicalutamide
Correct Answer(s)
C. Apalutamide
D. BicalutamideExplanation
Apalutamide and bicalutamide are both targeted therapies used for the treatment of prostate cancer. Apalutamide is an androgen receptor inhibitor that works by blocking the effects of androgens, which can fuel the growth of prostate cancer cells. Bicalutamide is also an androgen receptor inhibitor that works in a similar way. These targeted therapies are used in combination with other treatments, such as hormone therapy, to slow down the progression of prostate cancer and improve survival rates. Docetaxel and ibrutinib are not typically used as targeted therapies for prostate cancer.Rate this question:
-
- 14.
Checkpoint inhibitors block [ ] that hide the [ ] from attacking the cancer cells.
Correct Answer(s)
Proteins, T-cellsExplanation
Checkpoint inhibitors are a type of medication that block proteins that hide the T-cells from attacking cancer cells. T-cells are a crucial part of the immune system and play a role in recognizing and destroying abnormal cells, including cancer cells. However, cancer cells can sometimes evade detection by the immune system by expressing certain proteins that act as "checkpoints" and prevent T-cells from attacking them. Checkpoint inhibitors work by blocking these proteins, allowing the T-cells to recognize and attack the cancer cells effectively.Rate this question:
- 15.
Types of anticancer small molecules
- A.
3
- B.
4
- C.
5
- D.
6
Correct Answer
C. 5 -
- 16.
Which one below is the oral immuno-modulator ?
- A.
Lenalidomide
- B.
Imatinib
- C.
Lapatinib
- D.
Osimertinib
Correct Answer
A. LenalidomideExplanation
Lenalidomide is the oral immuno-modulator among the given options. It is a medication used to treat certain types of cancer and autoimmune diseases. It works by enhancing the immune system's response to cancer cells and reducing inflammation. Lenalidomide is known to modulate the immune system, making it an effective oral immuno-modulator. Imatinib, Lapatinib, and Osimertinib are not oral immuno-modulators; they belong to different drug classes and have different mechanisms of action.Rate this question:
-
- 17.
Which targeted therapy below does not have multiple indications:
- A.
Regorafenib
- B.
Cabozantinib
- C.
Sunitinib
- D.
Axitinib
Correct Answer
D. AxitinibExplanation
Axitinib is the targeted therapy that does not have multiple indications. This means that it is specifically used to treat a single condition or disease, unlike the other options (Regorafenib, Cabozantinib, and Sunitinib) which have multiple indications, meaning they can be used to treat various conditions or diseases.Rate this question:
-
- 18.
PARP inhibitors
- A.
Olaparib
- B.
Palbociclib
- C.
Niraparib
- D.
Cabozantinib
Correct Answer(s)
A. Olaparib
C. NiraparibExplanation
Olaparib and Niraparib are both PARP inhibitors. PARP inhibitors are a type of targeted therapy that work by blocking the enzyme poly ADP-ribose polymerase (PARP), which helps repair damaged DNA in cells. By inhibiting PARP, these drugs prevent cancer cells from repairing their DNA, leading to their death. Olaparib is approved for the treatment of ovarian, breast, and pancreatic cancers, while Niraparib is approved for the treatment of ovarian cancer. Palbociclib and Cabozantinib are not PARP inhibitors and have different mechanisms of action.Rate this question:
-
Quiz Review Timeline +
Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.
-
Current Version
-
Mar 21, 2023Quiz Edited by
ProProfs Editorial Team -
Apr 15, 2020Quiz Created by
Nabil
Back to top